Posted by Michael Wonder on 19 Jan 2016
Lilly and Incyte announce submission of new drug application to FDA for oral once-daily baricitinib for treatment of moderate-to-severe rheumatoid arthritis
19 January 2016 - If approved, Lilly will lead launch and global commercialization efforts for baricitinib in RA. Lilly owns global rights to develop and commercialize baricitinib as an oral treatment for all inflammatory conditions.
For more details, go to: https://investor.lilly.com/releasedetail.cfm?ReleaseID=950678https://investor.lilly.com/releasedetail.cfm?ReleaseID=950678
